Hemostasis Valve Market Size, Share, Regional Growth, 2026-2034

Market OverviewAccording to Fortune Business Insights, The global hemostasis valve market size was valued at USD 195.2 million in 2025. The market is projected to grow from USD 207.2 million in 2026 to USD 324.8 million by 2034, exhibiting a CAGR of 5.8% during the forecast period. North America dominated the global hemostasis valve market with a market share of 31.1% in 2025.

Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “Hemostasis Valve Market, 2026-2034.”

The analysis shows that the market is experiencing robust growth attributed to the increasing incidence of cardiovascular and neurovascular conditions necessitating catheter-based interventions. Currently, there is a rising shift toward one-handed, bloodless, and integrated systems. For instance, innovations like the PhD Hemostasis Valve streamline procedures using a simple one-handed push-and-release design. This trend, along with the integration of valves into introducer sheaths and radial access kits, supports procedural efficiency and signifies a strong demand for advanced hemostasis solutions globally.

Major Players Profiled in the Market Report:• Boston Scientific Corporation (U.S.)• B Braun SE (Germany)• Terumo Corporation (Japan)• Teleflex Incorporated (U.S.)• Abbott (U.S.)• Argon Medical Devices (U.S.)• Freudenberg Medical (Ireland)• Merit Medical Systems (U.S.)• SCW Medicath Ltd (China)• Shenzhen Antmed Co., Ltd. (China)

SegmentsIncreasing Adoption of Hemostasis Valves in Cath Labs to Drive Segmental GrowthBased on type, the market is classified into hemostasis valve Y-connectors, double Y-connector hemostasis valves, one-handed hemostasis valves, and others. The hemostasis valve Y-connectors segment holds the largest market share globally. This growth is mainly attributed to their essential role in coronary and peripheral angiography, allowing for simultaneous device passage and injection via dual ports, leading to high utilization in cath labs.

Rising Volume of Angiographies to Drive the Angiography Segment GrowthBy application, the market is segmented into angiography, angioplasty, neurovascular interventions, interventional radiology, and others. The angiography segment accounted for the largest share in 2025 (expected to hold a 41.2% share in 2026) due to the increasing volume of diagnostic coronary and peripheral angiographies worldwide, which routinely utilize Y-connector valves for contrast injection.

High Volume of Medical Interventions in Hospitals & ASCs Globally to Drive the Segment GrowthBased on end-user, the market is segmented into hospitals & ASCs, catheterization labs, specialty clinics, and others. The hospitals & ASCs segment dominates the market (set to hold a 63.3% share in 2026) owing to the high volume of PCI, neuro-interventions, and structural heart procedures performed in these settings.

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Report CoverageThe report offers:• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.• Comprehensive insights into regional developments, procedure volumes, and prevalence of key conditions.• List of major industry players and market share distributions.• Key strategies adopted by the market players.• The latest industry developments including product launches, approvals, technological innovations, and acquisitions.

Source: https://www.fortunebusinessinsights.com/hemostasis-valve-market-115049

Drivers & RestraintsSurging Adoption of Minimally Invasive Cardiovascular Procedures to Drive Market GrowthThe growing adoption of minimally invasive procedures, such as angiography and angioplasty, is a major factor driving market growth. Driven by an aging population and rising cardiovascular conditions, the U.S. alone sees over 500,000 percutaneous coronary interventions (PCI) annually. This creates a strong demand for reliable hemostasis valves at access sites to reduce blood loss and procedure time.

However, high costs and regulatory burdens restrict market expansion. Factors such as EU-MDR re-certification, raw material volatility, and value-based purchasing in developed countries are compressing costs for accessories. Furthermore, product recalls due to complications like leaks or air ingress pose a significant challenge to patient safety and overall market growth.

Regional InsightsDense Network of Healthcare Facilities Propels Market Growth in North AmericaNorth America holds the dominant hemostasis valve market share (valued at USD 60.7 million in 2025) and is projected to maintain its leadership. The region’s growth is attributed to a dense network of well-established hybrid operating rooms, cath labs, and ambulatory surgical centers (ASCs) that generate a regular demand for newer hemostasis valves. The U.S. market alone is expected to account for 29.3% of global revenue in 2026.

Europe is forecasted to achieve the second-highest growth rate globally (CAGR of 5.7%), reaching a market value of USD 61.1 million by 2026, driven by the strong presence of major manufacturers in Germany, the U.K., and France. Asia Pacific is emerging rapidly and is projected to reach USD 58.9 million in 2026, supported by substantial contributions from countries like China and India.

Hemostasis Valve Market Future Growth:The hemostasis valve market is poised for lucrative future growth, heavily fueled by expanding opportunities in emerging markets such as India, China, and Brazil, where patient pools for structural heart and neurovascular conditions are rapidly increasing. A prominent upcoming trend is the continued shift toward one-handed and integrated valve systems that elevate procedural efficiency. Additionally, major industry players are expected to capitalize on business-to-business (B2B) expansion through custom/OEM programs and private-label Y-connector sets, fostering strong partnerships with mid-sized catheter manufacturers globally.

Competitive LandscapePivotal Companies Hold Leading Market Positions Owing to their Procedure-specific PortfoliosThe market features prominent players like Merit Medical Systems, Teleflex Incorporated, and Argon Medical Devices holding dominant positions. These leading companies attribute their significant market share to broad, procedure-specific portfolios that are deeply penetrated across high-volume interventional settings. Other notable players, such as B. Braun SE and Terumo Corporation, are accelerating growth by expanding their global distribution footprints, building stronger relationships with hospitals, and scaling up their manufacturing capabilities to meet rising global demand.

Key Industry Developments• February 2025: Teleflex Incorporated announced BIOTRONIK’s Vascular Intervention business’s plans to scale up its coronary and peripheral portfolio.• February 2024: Terumo Corporation broke ground on a new 64,000-square-foot manufacturing facility at its Puerto Rico site to meet rising global demand for the Angio-Seal Vascular Closure Device.• November 2023: Cerenovus obtained FDA 510(k) clearance for the CEREGLIDE™ 92 Intermediate Catheter, which uses a Borst hemostasis valve with side port and slit introducers.